Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy

By            

Molecular Medicine Reports, Vol. 7, Iss. 2, 2013-01 ,pp. : 613-617

Spandidos Publications

Access to resources Recommend Favorite

Association between chemotherapy and cognitive impairments in a large cohort of patients with colorectal cancer

By      

International Journal of Oncology, Vol. 42, Iss. 6, 2013-01 ,pp. : 2123-2133

Spandidos Publications

Access to resources Recommend Favorite

CEA and CA19.9 as Early Predictors of Progression in Advanced/Metastatic Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy and Bevacizumab

By Petrioli Roberto   Licchetta Antonella   Roviello Giandomenico   Pascucci Alessandra   Francini Edoardo   Bargagli Gianluca   Conca Raffaele   Miano Salvatora Tindara   Marzocca Giuseppe   Francini Guido    

Cancer Investigation, Vol. 30, Iss. 1, 2012-01 ,pp. : 65-71

Informa Healthcare

Access to resources Recommend Favorite

Neoadjuvant chemotherapy in young breast cancer patients: correlation between response and relapse?

By Braud A.C.   Asselain B.   Scholl S.   De La Rochefordiere   Palangie T.   Dieras V.   Pierga J.Y.   Dorval T.   Jouve M.   Beuzeboc P.   Pouillart P.  

European Journal of Cancer, Vol. 35, Iss. 3, 1999-03 ,pp. : 392-397

Elsevier

Access to resources Recommend Favorite

Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience

By Shimizu Toshio   Satoh Taroh   Tamura Kenji   Ozaki Tomohiro   Okamoto Isamu   Fukuoka Masahiro   Nakagawa Kazuhiko  

International Journal of Clinical Oncology, Vol. 12, Iss. 3, 2007-06 ,pp. : 218-223

Springer Publishing Company

Access to resources Recommend Favorite